The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by University of Rochester.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by (Responsible Party):
MarcSwogger, University of Rochester
ClinicalTrials.gov Identifier:
NCT01532934
First received: January 31, 2012
Last updated: February 10, 2012
Last verified: February 2012
  Purpose

Substance use among criminal offenders constitutes a major public health problem and is tied to negative consequences for offenders, their families, and their communities. One of the direst of these consequences is repeated incarceration; thus, interventions that reduce criminal recidivism are needed. Forensic populations are often viewed with considerable therapeutic pessimism. However, offenders exhibit heterogeneity in personality traits, and the assessment of individual differences among offenders may provide valuable information that guides the use of psychotherapeutic interventions. Among offenders, psychopathy has emerged as an important personality construct for the understanding of violence and criminal recidivism. Moreover, core traits of psychopathy such as lack of empathy, deceitfulness, and lack of remorse may have negative implications for the efficacy of psychosocial interventions. A foundational premise of the present work is that understanding the moderating role of psychopathic traits on substance use treatment outcomes among offenders is essential to determining what works, and for whom. The current proposal is a Phase II randomized clinical trial that aims to examine the impact of psychopathic traits on the efficacy of a brief substance use intervention for offenders in a jail diversion program. Hypotheses that will be examined include: 1) that a Motivational Interviewing (MI) - based treatment will reduce substance use and related consequences relative to a Standard Care only condition, 2) that the reduction in substance use in the intervention group will mediate a reduction in later criminal recidivism relative to the Standard Care condition, and 3) that core psychopathic traits will moderate the efficacy of the intervention such that individuals with lower levels of these traits will derive greater benefits with regard to decreased substance use, decreased drug use consequences, and decreased criminal recidivism at a one-year follow-up.


Condition Intervention Phase
Substance Use
Psychopathy
Behavioral: motivational enhancement therapy
Other: standard care
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: The Impact of Psychopathic Traits on the Efficacy of a Brief Intervention for Substance Use

Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • criminal recidivism [ Time Frame: one year ] [ Designated as safety issue: No ]
    criminal charges within one year


Secondary Outcome Measures:
  • substance use [ Time Frame: six months ] [ Designated as safety issue: No ]
    using timeline followback data, use of substances will be assessed


Estimated Enrollment: 120
Study Start Date: August 2009
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: brief therapy
motivational enhancement therapy for substance use
Behavioral: motivational enhancement therapy
Four 45-minute MET sessions
Other Name: SBIRT
Placebo Comparator: Standard Care
standard care
Other: standard care
standard care

Detailed Description:

Substance use among criminal offenders constitutes a major public health problem and is tied to negative consequences for offenders, their families, and their communities. One of the direst of these consequences is repeated incarceration; thus, interventions that reduce criminal recidivism are needed. Forensic populations are often viewed with considerable therapeutic pessimism. However, offenders exhibit heterogeneity in personality traits, and the assessment of individual differences among offenders may provide valuable information that guides the use of psychotherapeutic interventions. Among offenders, psychopathy has emerged as an important personality construct for the understanding of violence and criminal recidivism. Moreover, core traits of psychopathy such as lack of empathy, deceitfulness, and lack of remorse may have negative implications for the efficacy of psychosocial interventions. A foundational premise of the present work is that understanding the moderating role of psychopathic traits on substance use treatment outcomes among offenders is essential to determining what works, and for whom. The current proposal is a Phase II randomized clinical trial that aims to examine the impact of psychopathic traits on the efficacy of a brief substance use intervention for offenders in a jail diversion program. Hypotheses that will be examined include: 1) that a Motivational Interviewing (MI) - based treatment will reduce substance use and related consequences relative to a Standard Care only condition, 2) that the reduction in substance use in the intervention group will mediate a reduction in later criminal recidivism relative to the Standard Care condition, and 3) that core psychopathic traits will moderate the efficacy of the intervention such that individuals with lower levels of these traits will derive greater benefits with regard to decreased substance use, decreased drug use consequences, and decreased criminal recidivism at a one-year follow-up. This work has the potential to provide important data regarding which individuals can benefit from a brief intervention for substance use. Such data will inform the effective and efficient allocation of treatment resources for substance using offenders.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In local pretrial services program; English speaking

Exclusion Criteria:

  • Psychosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01532934

Contacts
Contact: Marc T. Swogger, Ph.D. 585-275-7418 marc_swogger@urmc.rochester.edu

Locations
United States, New York
Pretrial Services, Inc. Recruiting
Rochester, New York, United States, 14642
Principal Investigator: Marc T. Swogger, Ph.D.         
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Marc T. Swogger, Ph.D. University of Rochester
  More Information

No publications provided

Responsible Party: MarcSwogger, Assistant Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT01532934     History of Changes
Other Study ID Numbers: 28780
Study First Received: January 31, 2012
Last Updated: February 10, 2012
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by University of Rochester:
substance use
psychopathy
motivational enhancement
criminal recidivism

Additional relevant MeSH terms:
Antisocial Personality Disorder
Personality Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2014